In late December 2019, a novel coronavirus, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), escaped the animal–human interface and emerged as an ongoing global pandemic with severe flu-like illness, commonly known as coronavirus disease 2019 (COVID-19). In this study, a molecular docking study was carried out for seventeen (17) structural analogues prepared from natural maslinic and oleanolic acids, screened against SARS-CoV-2 main protease. Fur-thermore, we experimentally validated the virtual data by measuring the half-maximal cytotoxic and inhibitory concentrations of each compound. Interestingly, the chlorinated isoxazole linked maslinic acid (compound 17) showed promising antiviral activity at micromolar non-toxic concentrations. Thoughtfully, we showed that compound 17 mainly impairs the viral replication of SARS-CoV-2. Furthermore, a very promising SAR study for the examined compounds was concluded, which could be used by medicinal chemists in the near future for the design and synthesis of potential anti-SARS-CoV-2 candidates. Our results could be very promising for performing further additional in vitro and in vivo studies on the tested compound (17) before further licensing for COVID-19 treatment.
CITATION STYLE
Soltane, R., Chrouda, A., Mostafa, A., Al-Karmalawy, A. A., Chouaïb, K., Dhahri, A., … Ali, M. A. (2021). Strong inhibitory activity and action modes of synthetic maslinic acid derivative on highly pathogenic coronaviruses: Covid-19 drug candidate. Pathogens, 10(5). https://doi.org/10.3390/pathogens10050623
Mendeley helps you to discover research relevant for your work.